Here's an example of recent hard work by the Geth team that makes these kinds of scale increases safe.https://t.co/Wgi2F7mbUWMariusVanDerWijden (@vdWijden):Geth v.1.16.0 finally ships the PBSS based archive node, you can have a geth archive node in ca. 1.9TB (down from 20+TB)🚀🚀Queries against historical states (What was my balance at block X) are possible, proofs against historical states are not (yet)Great work by @Gary_Rong ...

The stock market is a bank, if you approach it the right way (from Tom Gardner, Co-Founder and CEO of The Motley Fool). https://t.co/bi3N5VrQSE ...

Core Viewpoint - Lucid Motors is considering a 1-for-10 reverse stock split to potentially enhance its stock attractiveness to institutional investors, despite the market generally viewing such moves negatively [2][9]. Group 1: Reverse Stock Split Details - Lucid Motors filed a preliminary proxy statement with the SEC for a special stockholders' meeting to authorize a reverse stock split at a ratio of 1-for-10 [2]. - A 1-for-10 reverse stock split means that Lucid will reduce its outstanding shares by a factor of 10, combining 10 old shares into one new share, which will increase the stock price proportionally [3]. - The reverse stock split does not change the overall market capitalization or the value of what investors own, as the stock price adjusts in accordance with the reduction in shares [4]. Group 2: Implications and Market Perception - While reverse stock splits are often associated with companies at risk of delisting due to low stock prices, Lucid's current trading price of approximately $3.15 per share does not place it in immediate danger [5][6]. - The potential upside of the reverse stock split is to attract institutional investors who may have policies against owning stocks below a certain price, thereby increasing demand for Lucid's shares [8]. - The market typically views reverse stock splits negatively, associating them with financial distress and falling stock prices, which may not be favorable for investment perception [9]. Group 3: Company Performance and Future Outlook - Lucid Motors is currently experiencing cash burn but has shown consistent delivery growth over the past seven quarters, with future performance hinging on the success of its new electric Gravity SUV and upcoming midsize platform [10]. - The company has sufficient liquidity to fund operations through the second half of 2026, indicating a level of financial stability despite the high-risk nature of its stock [11].

Core Viewpoint - President Trump's trade policies, particularly aggressive tariffs on imports, are impacting Wall Street and could increase costs for companies, affecting their margins and stock performance. However, certain healthcare companies like Eli Lilly and Novartis present investment opportunities despite these challenges [1][2]. Eli Lilly - Eli Lilly has committed to investing $50 billion in U.S.-based manufacturing since 2020, with half of this announced in the first quarter [4]. - The company aims to manufacture 100% of medicines for U.S. patients domestically, which will help mitigate the impact of tariffs [5]. - Eli Lilly has shown significant innovation in diabetes and obesity treatments, with new products like Mounjaro and Zepbound generating billions in revenue [5]. - In Q1, Eli Lilly's revenue rose 45% year over year to $12.7 billion, and net income increased by 23% to $2.8 billion [6]. - The company has a strong pipeline, including a promising oral GLP-1 candidate, orforglipron, which could attract patients seeking convenience [7]. - Eli Lilly has increased its dividend payout by 102.7% over the past five years, making it a solid choice for growth and income investors [8]. Novartis - Novartis plans to invest $23 billion over the next five years to enhance its U.S. manufacturing capabilities [9]. - Despite potential short-term impacts from tariffs, Novartis is expected to manage these challenges effectively [10]. - In Q1, Novartis reported a 12% increase in net sales to $13.2 billion and a 22% rise in net income to $4.5 billion [10]. - The company is facing a loss of U.S. patent exclusivity for its heart failure drug Entresto, which generated $2.3 billion in sales in Q1, a 20% increase year over year [11]. - Novartis has prepared for this loss with new medicines like Fabhalta and cancer drugs Scemblix and Pluvicto, which have shown promising sales [11][12]. - The company has increased its dividend for 28 consecutive years, currently offering a forward yield of 3.3%, which is significantly higher than the S&P 500 average [13].

De Beers convinced the world that love wasn’t real without a diamond. Now it's struggling to convince us we shouldn't just buy a cheaper lab-grown stone. 🔗 https://t.co/7LQJC7FviT https://t.co/kNVSB797Fu ...

RT Jrag.eth (@Jrag0x)How long does the "store of value" meta actually last? ...

One of my family members has retired recently, and he's allocated a sizeable amount of his retirement capital towards a dividend ETF. He chose the most popular dividend ETF, Schwab U.S. Dividend Equity ETF ( SCHDFinancial analyst by day and a seasoned investor by passion, I've been involved in the world of investing for over 15 years and honed my skills in analyzing lucrative opportunities within the market.I specialize in uncovering high quality dividend stocks and other assets that offer potential for lon ...

Group 1 - Gold is highlighted as the only precious metal that should be included in investment portfolios due to its historical performance in protecting value during market downturns and generating alpha since the 1970s [1] - The analyst, known as The Barnacle, emphasizes a quantitative approach to investing, valuing mathematical analysis over sell-side analysis, which is often deemed inadequate [1] - The investment strategy includes a focus on value stocks with growth potential across various market capitalizations, including large caps, midcaps, small caps, international stocks, gold miners, and REITs [1] Group 2 - The analyst has a beneficial long position in AEM shares, indicating a personal investment interest in the company [2] - The article expresses the analyst's own opinions without external compensation, suggesting an independent viewpoint on the investment landscape [2]

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth.Does the prospect of economic uncertainty have you rethinking your portfolio? Perhaps you'd like to collect a little more cash while the economic headwinds are blowing? It's not an unreasonable concern. Plenty of other investors are already thinking more defensively than they've felt they needed to in a while.To this end, here's a closer look at five high-yielding dividend stocks to ...

➢ 短期来看，我们认为跨境支付场景有望成为稳定币落地应用的重要场景，稳 定币有望助力提升跨境支付效率、降低跨境支付成本，跨境支付相关金融科技标 的有望持续受益，建议重点关注连连数字。 ➢ 长期来看，稳定币有望推动虚拟资产交易和 RWA（Real World Asset，现 实世界资产代币化）、STO（Security Token Offering，证券代币化），稳定币 有望助力传统金融资产进行"链上"交易，中资券商加速布局，例如国泰君安国 际升级虚拟资产交易牌照、广发证券（香港）已全面接入 HashKey Chain 作为 核心链上发行网络，并发行首个每日可申赎代币化证券"GF Token"，头部券商 和交易所标的有望更为受益稳定币发展，建议重点关注香港交易所、中信证券、 华泰证券、国泰海通和中国银河等标的。 中国香港《稳定币条例》生效在即，重视头部券商及跨境支付 2025 年 07 月 20 日 ➢ 中国香港《稳定币条例》即将于 8 月 1 日正式生效，"沙盒试验"不断推 进，技术架构、合规性及实际应用场景有望不断完善，有望推动中国香港稳定币 相关产业发展，同时美国国会众议院于 7 月 17 日以 308 ...